

Original Research Article

**Vascular Endothelial Growth Factor Gene Polymorphisms in
Type 2 Diabetes Mellitus; Insertion/Deletion at -2549 is Associated
with Retinopathy but not + 405 G/C Polymorphism**

ABSTRACT

Background: Retinopathy is a serious ocular complication of diabetes. Vascular endothelial growth factor (VEGF) is massively unregulated in diabetic retinopathy. The objective of this study was to investigate the G + 405 C polymorphism in the 5'-untranslated region and the I/D polymorphism at the – 2549 position of the promoter region of the VEGF gene in patients with type 2 diabetes mellitus.

Methodology: In this study, 103 unrelated type 2 diabetic patients and 40 control subjects were involved in a case-control design. Genotyping of the I/D polymorphism at -2549 was analyzed by PCR and the G/C +405 polymorphism by PCR-RFLP.

Results: For +405 G/C polymorphism, there is no statistical significant difference in genotype distribution and allele frequencies in both diabetes groups when compared to control group or to each other. While I/D polymorphism at -2549 shows significant increase in ID genotype distribution in diabetes without and with retinopathy groups versus control group [OR (CI) =3.67 (1.27-10.8) & 5.5 (1.98-

15.73) and $P = 0.01$ & < 0.001 , respectively]. I allele is significantly increased in diabetes without and with retinopathy groups versus control group [OR (CI) = 3.99 (1.8-8.97) & 3.98 (1.84-8.71), respectively and $P < 0.001$ for both]. There is no significant difference in genotype and allele frequencies in both diabetes groups when compared to each other ($P = 0.59$ & 0.99 , respectively).

Conclusions: Heterozygous form of I/D polymorphism and I allele at -2549 of VEGF gene might possibly be associated with a higher susceptibility to retinopathy as a complication of type 2 diabetes mellitus. While, no association was found with VEGF +405 G/C gene polymorphism.

Keywords: VEGF gene, Diabetic Retinopathy, -2549 I/D polymorphism, +405 G/C gene polymorphism, Type 2 Diabetes

1. INTRODUCTION

Diabetic retinopathy (DR) is one of the most prominent vascular complications in diabetes and is the most common cause of blindness among diabetic adults [1]. It is characterized by increased vascular permeability, tissue ischemia and angiogenesis [2]. DR progresses from non-proliferative (background diabetic retinopathy) into proliferative (high-risk proliferative retinopathy) and finally advanced diabetic eye disease which is accompanied by recurrent

41 hemorrhage and fibrosis, this results in tractional retinal detachment and
42 neovascular glaucoma [1].

43 The pathogenesis of DR is influenced by environmental and genetic factors.
44 Ethnic differences in the prevalence of DR may offer understandings into the
45 relative importance of genetic or environmental risk factors. Therefore, it is
46 important to identify molecular markers that may help in the diagnosis of DR in
47 multiple populations [3].

48 Vascular endothelial growth factor (VEGF) is one of the most potent
49 endothelial cell mitogens and plays a critical role in angiogenesis [4]. It is a highly
50 conserved homodimeric glycoprotein [5], which specifically binds to two
51 transmembrane VEGF tyrosine kinase receptors on endothelial cells to initiate
52 intracellular signal transduction pathways that mediate angiogenesis and vascular
53 permeability [4]. VEGF is massively unregulated in DR and not only promotes
54 neovascularization but also increases vascular permeability and leakage [6]. It is
55 produced from many cell types within the eye [5] and plays a key role in the
56 pathogenesis of diabetic microvascular complications [6].

57 Several studies have shown that VEGF expression is increased in patients
58 with DR [7, 8] and others documented that VEGF levels are markedly elevated in
59 vitreous of the eyes of individuals with proliferative DR [9]. The genetic variations
60 in the VEGF gene can influence levels of VEGF protein expression [2].

The human VEGF gene is located on chromosome 6 (6p21.3) and is highly polymorphic. It includes eight exons and seven introns. Of particular interest is an insertion/deletion (I/D) polymorphism of the 18 base pair (bp) fragment at – 2549 position of the promoter region that has been implicated in a number of diseases, especially those with angiogenic basis [10, 11]. Also, at least 30 single-nucleotide polymorphisms (SNP) in this gene have been described. The G + 405 C (rs2010963) polymorphism in the 5'-untranslated region is a common SNP and is related to VEGF protein production [12, 13]. The +405 G/C polymorphism alters the activity of the internal ribosomal entry site B enhancing initiation of translation at the AUG start codon. Also, regulates the production of the large VEGF isoform translated at an alternative CUG codon. Therefore, it is believed that the +405 G/C polymorphism likely affects expression at the post-transcriptional level [14, 15].

The purpose of this study was to investigate the G + 405 C polymorphism in the 5'-untranslated region and the I/D polymorphism of the 18 bp fragment at the – 2549 position of the promoter region of the VEGF gene in patients with type 2 diabetes mellitus and to assess their possible role in the risk of developing diabetic retinopathy.

2. METHODS

A case-control study enrolled 143 subject; 103 unrelated type 2 diabetic patients and 40 controls was conducted. Diagnosis of type 2 diabetes based on the current American Diabetes Association Criteria for the Diagnosis and Classification of Diabetes [16]. Diabetic patients were classified into two groups. Diabetes without retinopathy group (46 patients) recruited from Diabetic & Endocrinology Unit at Specialized Medical Hospital, Mansoura University, Egypt. After careful fundus examination to exclude any retinopathy. Diabetes with retinopathy group (57 patients) recruited from Mansoura Ophthalmic Centre, Mansoura University, Egypt.

Control subjects were unrelated healthy volunteers with matched age and sex with no history of diabetes or any major clinical disorders and had normal glycosylated hemoglobin (HbA1c). Also, careful fundus examination was done to exclude any retinopathy. Also, HbA1c was measured for all diabetic patients. Fully informed and written consent was obtained from all participants. The protocol of the study was approved by the Institutional Ethics Committee and in accordance with the guidelines of the Declaration of Helsinki.

2.1 Samples collection and DNA extraction:

Venous blood samples (6 ml) were obtained on EDTA containing tubes from all patients and control subjects; 1ml of the sample was used for HbA1c estimation (COBAS, INTEGR, Roche Diagnostics, USA). Genomic DNA was isolated from

100 peripheral blood leukocyte using the QiaAmp kit (Qiagen, GmbH, USA). The
101 extracted DNA was stored at -20°C until analysis.

102 *2.2 VEGF gene I/D polymorphism at -2549 analysis:*

103 Genotyping of the I/D polymorphism was analyzed by polymerase chain
104 reaction (PCR) using the following primers: forward 5'-
105 GCTGAGAGTGGGGCTGACTAGGTA-3' and reverse 5'-
106 GTTTCTGACCTGGCTATTTCCAGG-3'. PCR amplification was performed
107 using Dream Tag Green PCR Master Mix (Fermentas, USA). Genomic DNA (300
108 ng) was amplified in a final volume of 30 µl using the following conditions:
109 denaturation at 95°C for 6 min followed by 35 cycles at 94°C for 1 min, 57°C for
110 1.5 min and 72°C for 2 min. A final extension was at 72°C for 10 min. The
111 amplification products were separated by electrophoresis on 2.5% agarose gel
112 stained with ethidium bromide; GeneRuler 50 bp DNA ladder (Fermentas, USA)
113 was used as a marker. For the VEGF I/D polymorphism two bands were observed,
114 211 bp for D allele and 229 bp for I allele (Figure 1).





Figure 1: VEGF gene I/D polymorphism at -2549. Marker ladder, lane M; II genotype (229 bp), for example lane 2; DD genotype (211 bp), for example lanes 5, 8; and ID genotype (211 and 229 bp), for example lanes 3, 4, 6 & 10.

2.3 VEGF gene +405 G/C polymorphism analysis:

VEGF +405 G/C polymorphism was analyzed by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). PCR amplification performed as described above using 5'-ATTTATTTTGGCTTGCCATT-3' and 5'-GTCTGTCTGTCTGTCCGTCA-3' as the forward and reverse primer pairs, respectively. Then the PCR product was digested with FastDigest BsmFI (Thermo Scientific, USA) restriction nuclease at 37 °C_overnight. The digestion products were separated by electrophoresis through 2.5% agarose gel stained with ethidium

128 bromide; GeneRuler 50 bp DNA ladder (Germentas, USA) was used as a marker.
 129 The uncut fragment was 304 bp (C allele) and digestion products were 193 and 111
 130 bp (G allele) (Figure 2).



131
 132 **Figure 2:** VEGF gene +405 G/C polymorphism. Marker ladder, lane M; CC genotype (304 bp),
 133 for example lane 3; GG genotype (193 and 111 bp), for example lane 10; and GC genotype (304,
 134 193 and 111 bp), for example lanes 7&11.

135

136 2.4 Statistical analysis:

137 Statistical analyses of data were done by Statistical Package for Social
 138 Science version 22 (SPSS, Inc., Chicago, IL). Qualitative variables expressed as
 139 number and percentage. Quantitative variables expressed as mean $\pm$ standard
 140 deviation. Statistical significance was defined as P value ≤ 0.05 . For quantitative
 141 data, student t-test was used to compare between two groups. Repeated measure
 142 ANOVA to compare same group in different times followed by post Hoc test for

143 intra-time comparison. Chi square test was used for qualitative data and odds ratio
144 & 95% confidence interval (OR & 95% CI) for risk assessment.

145

146 3. RESULTS

147 The characteristics of patients and control subjects are listed in Table 1.
148 There is significant difference in HbA1c in the three groups ($P < 0.001$). Pairwise
149 comparison revealed significant increase in HbA1c in both diabetes groups versus
150 control group ($P < 0.001$, for both) and in diabetes with retinopathy versus without
151 retinopathy ($P = 0.002$) (not shown in the table).

152 **Table 1: Characteristics of the control, diabetes with and without retinopathy groups.**

	Control (n= 40)	Diabetes without retinopathy (n=46)	Diabetes with retinopathy (n=57)	<i>P</i>
Age (years)	47.88 ± 7.1	46.72 ± 4.58	48.75 ± 6.13	0.23
Sex:				
Male	18 (45)	20 (43.5)	28 (49.1)	0.84
Female	22 (55)	26 (56.5)	29 (50.9)	
Diabetes duration (years)	-	10.13 ± 3.92	11.63 ± 4.7	0.2
HbA _{1c} (%)	5.24 ± 0.86	7.69 ± 0.65	8.24 ± 1.0	0.000*

153

154 Data are number (%) & mean $\pm$ SD. *: Significant (P = 0.05).

155

156 *3.1 VEGF gene +405 G/C polymorphism:*

157 There is no significant difference in genotype distribution and allele
158 frequency in the diabetes groups (without and with retinopathy) when compared to
159 the control group or to each other (Table 2).

160 **Table 2: Genotype and allele frequencies of the G + 405C polymorphism in the control, diabetes without and**
 161 **with retinopathy groups.**

	Control (n= 40)	Diabetes without retinopathy (n= 46)	Diabetes with retinopathy (n= 57)	Diabetes without retinopathy versus control			Diabetes with retinopathy versus control		
				OR (CI)	Pearson χ^2 (df.=2)	P	OR (CI)	Pearson χ^2 (df.=2)	P
Genotype									
CC	32 (80)	28 (60.9)	39 (68.4)	0.39 [0.13-1.14]	2.86	0.09	0.46 [0.16-1.3]	1.94	0.16
GC	6 (15)	14 (30.4)	14 (24.6)	2.48 [0.76-8.33]	2.06	0.15	1.72 [0.54-5.66]	0.59	0.44
GG	2 (5)	4 (8.7)	4 (7.0)	1.81[0.26-15.21]	0.06	0.8	2.51 [0.44-18.59]	0.62	0.43
		$P' = 0.73$							
Allele: C	70 (87.5)	70 (76.1)	92 (80.7)	0.45 [0.18-1.1]			0.6 [0.025-1.43]		
G	10 (12.5)	22 (23.9)	22 (19.3)	2.2 [0.91-5.41]	2.97	0.08	1.67 [0.7-4.07]	1.12	0.28
		$P' = 0.42$							

162 Data are number (%); OR, odd ratio; CI, confidence interval. *: Significant (P = 0.05).

163 P' : for diabetes without versus with retinopathy groups.

164 *3.2 VEGF gene I/D polymorphism at -2549:*

165 There is significant increase in DD genotype distribution in control group
166 versus both diabetes groups [OR (CI) =0.18 (0.06-0.5) & 0.14 (0.05-0.39) for
167 diabetes without and with retinopathy groups, respectively and $P < 0.001$, for both].
168 While, there is significant increase in ID genotype distribution in both diabetes
169 without and with retinopathy groups versus control [OR (CI) =3.67 (1.27-10.8) &
170 5.5 (1.98-15.73) and $P = 0.01$ & < 0.001 , respectively]. However, there is no
171 significant difference for II genotype distribution in both diabetes groups versus
172 control group. I allele is significantly increased in diabetes without and with
173 retinopathy groups versus control group [OR (CI) =3.99 (1.8-8.97) & 3.98 (1.84-
174 8.71), respectively and $P < 0.001$ for both]. Meanwhile, D allele is significantly
175 increased in controls. There is no significant difference in genotype distribution
176 and allele frequency in both diabetes groups (without and with retinopathy) when
177 compared to each other ($P = 0.59$ & 0.99 , respectively) (Table 3).

178 **Table 3: Distribution of I/D polymorphism at – 2549 position of the promoter region in the control, diabetes**
 179 **without and with retinopathy groups.**

	Control (n= 40)	Diabetes without retinopathy (n= 46)	Diabetes with retinopathy (n= 57)	Diabetes without retinopathy versus control			Diabetes with retinopathy versus control		
				OR (CI)	Pearson χ^2 (df.=2)	P	OR (CI)	Pearson χ^2 (df.=2)	P
Genotype									
DD	30 (75)	16 (34.8)	17 (29.8)	0.18 [0.06-0.5]	12.34	<0.001*	0.14 [0.05-0.39]	17.4	<0.001*
ID	8 (20)	22 (47.8)	33 (57.9)	3.67 [1.27-10.8]	6.12	0.01*	5.5 [1.98-15.73]	12.3	<0.001*
II	2 (5)	8 (17.4)	7 (12.3)	4 [0.71-29.3]	2.1	0.14	2.66[0.46-19.74]	0.74	0.38
		$P' = 0.59$							
Allele: D	68 (85)	54 (58.7)	67 (58.8)	0.25 [0.11-0.56]			0.25 [0.11-0.54]		
I	12 (15)	38 (41.3)	47 (41.2%)	3.99 [1.8-8.97]	13.11	<0.001*	3.98 [1.84-8.71]	14.07	<0.001*
		$P' = 0.99$							

180 Data are number (%); OR, odd ratio; CI, confidence interval.

181 : Significant (P<0.05); P' : for diabetes without versus with retinopathy groups

4. DISCUSSION

Retinopathy is a serious ocular complication of diabetes that causes loss of vision in adults [17]. DR is characterized by increased vascular permeability, tissue ischemia and neovascularization. VEGF can stimulate angiogenesis and increases the permeability of the microvasculature [18] and has been implicated in the development of diabetic retinopathy [11]. It has been suggested that VEGF protein expression is affected by genetic variant in the VEGF gene [18].

In the present study, no significant association was found between VEGF +405 G/C gene polymorphism and DR. This result is in accordance with Watson et al. [12], Ray et al. [19] and Buraczynska et al. [11] who found no significant association between retinopathy status and the VEGF +405 polymorphism. Uthra et al. [20] and Petrovič et al. [21] reported no significant association between the rs2010963 (+405 G/C in this study) and DR. In addition, Bleda et al. [22] analyze the VEGF gene +405 polymorphism and found no association with DR but when analyze allele frequency; they observed that the presence of the G allele is a risk marker for developing retinopathy. Lu et al. [18] in their meta-analysis found that VEGF rs2010963 (+405 G/C) polymorphism was not associated with diabetic retinopathy in both Europeans and East Asians ethnicity. Also, Han et al. [3] in their met-analysis confirm the non-significant association between VEGF rs2010963 polymorphism and DR.

The result is contradictory with Awata et al. [2] where +405 polymorphism was strongly associated with DR in Japanese subjects. Suganthalakshmi et al. [23] found the heterozygous form is significantly higher in patients with diabetic retinopathy compared with diabetic without retinopathy. While, Szaflik et al. [24] found that the C allele of VEGF +405 polymorphism was associated with an increased risk of DR. This discrepancy might be due to different ethnicity of the patients or may be related to other contributing factors among those populations that need further exploration.

Also, the same patients and controls have been screened for VEGF gene I/D polymorphism of the 18 bp fragment at -2549 position of the promoter region. The current study showed a significant association of ID genotype and I allele with retinopathy in diabetic patients when compared to healthy control group, while no significant difference was found when compared to diabetes without retinopathy group. The results in accordance with that obtained by Bleda et al. [22] where the ID genotype was identified as a potential risk marker of diabetic retinopathy. Moreover, the result is partly in accordance with Foad et al. [25] who found no significant difference in genotype distribution and allele frequency in diabetic patients with retinopathy, diabetics without retinopathy and control subjects.

In contrast, Awata et al. [2] and Buraczynska et al. [11] found an association between the DD genotype and increase in the risk of DR. The discrepant findings

222 might be due to differences in the statistical power, the recruitment of studied
223 population, the type of retinopathy, and the genetic and environmental
224 backgrounds.

225 It is well established that DR is determined by both genetic and
226 environmental factors. It would be useful to identify molecular markers that may
227 help to predict the development of retinopathy at earlier stages of diabetes [18]. In
228 this study, we have focused on the 5'-untranslated region and promoter region of
229 VEGF gene for genetic analysis as they have been shown to be highly
230 polymorphic. In addition, most of the hypoxia responsive elements are present in
231 these regions and retinal hypoxia has been observed in DR. During hypoxia,
232 hypoxia-inducible factors bind to the hypoxia-response elements and induce the
233 expression of VEGF, which leads to the stimulation of angiogenesis [23].
234 Moreover, VEGF could induce the earliest changes in retinopathy including
235 leukostasis, blood-retinal barrier breakdown, and macular edema &
236 neovascularization in progression of DR. In addition, VEGF inhibition has been
237 indicated to cause a marked reduction in retinal neovascularization and prevention
238 of the blood–retinal barrier breakdown [18].

239 The current study also showed that diabetes with retinopathy group is
240 associated with higher level of HbA_{1C} than in controls and diabetes without
241 retinopathy group. This result is in harmony with Stratton et al. [26] who confirmed

the steep association between HbA1c exposures and both incidence and progression of DR in type 2 diabetes. Longo-Mbenza et al. [27] found significant association of poor control of HbA1c (poor glycemic control) and long-term microvascular complications of diabetes as DR in African patients. Moreover, Foad et al. [25] found that Glycosylated hemoglobin was significantly higher in diabetic patients (with and without retinopathy) than in controls.

Hyperglycemia has been recognized as the primary pathogenic factor in the development and progression of diabetic retinopathy [28]. Several biochemical pathways are supposed to be activated secondary to hyperglycemia. These abnormal pathways in turn, may influence several vasoactive factors that are likely to create functional and morphological changes in the retina of patients with diabetes [17]. Furthermore, improving control of blood glucose reduced development of retinopathy [29].

5. CONCLUSION

The present study suggests that, the heterozygous form of I/D polymorphism and I allele at -2549 of VEGF gene might possibly be associated with a higher susceptibility to retinopathy as a complication of type 2 diabetes mellitus. While, no association is found with VEGF +405 G/C gene polymorphism. Further well-designed large-scale studies with the consideration of gene-gene and gene-

environment interactions should be conducted to investigate the association is recommended.

6. REFERENCES

1- Early Treatment Diabetic Retinopathy Study Research Group. Risk factors for proliferative diabetic retinopathy and severe visual loss. *Invest Ophthalmol Vis Sci* 1998; 39: 233-52.

2- Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S. A common polymorphism in the 5'- untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. *Diabetes* 2002; 51:1635–1639.

3- Han L, Zhang L, Xing W, Zhuo R, Lin XL, Hao Y, Wu Q, Zhao J. The Associations between VEGF Gene Polymorphisms and Diabetic Retinopathy Susceptibility: A Meta-Analysis of 11 Case-Control Studies. *J Diabetes Res* 2014; Article ID 805801: 10 pages.

4- Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. *Nat Med* 2003; 9: 669–76.

5- Zhou L, Sun H, Xu J, Kang J. Level of vascular endothelial growth factor and interleukin-6 in aqueous humor in diabetic retinopathy patients. *Yan Ke Xue Bao* 2010; 25(1):26- 30.

- 282 6- Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor.
283 Endocr Rev 1997; 18: 4–25.
- 284 7- Cavusoglu A C, Bilgili S, Alaluf A, Doğan A, Yilmaz F, Aslanca D, Karaca B,
285 Yüksel B, Topaloglu E. Vascular endothelial growth factor level in the serum of
286 diabetic patients with retinopathy. Ann Ophthalmol (Skokie) 2007; 39(3): 205-208.
- 287 8- Yan H, Cui J, Yu JG, Han JD, Chen S, Zhang JK, Xu YH. The expression of
288 vascular endothelial growth factor of vitreous in patients with proliferative diabetic
289 retinopathy. Zhonghua Yan Ke Za Zhi 2009; 45 (3): 206-209.
- 290 9- Kant S, Seth G, Anthony K. Vascular endothelial growth factor-A (VEGF-A) in
291 vitreous fluid of patients with proliferative diabetic retinopathy. Ann Ophthalmol
292 (Skokie) 2009; 41(3-4):170-173.
- 293 10- Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular
294 endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996;
295 93:1493–1495.
- 296 11- Buraczynska M, Ksiazek P, Baranowicz- Gaszczyk I, Jozwiak I. Association of
297 the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes
298 patients. Nephrol Dial Transplant 2007; 22: 827–832.
- 299 12- Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC. Identification of
300 polymorphisms within the vascular endothelial growth factor gene: correlation
301 with variation in VEGF protein production. Cytokine 2000; 12: 1232–5.

- 13- Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. *Cancer Res* 2003; 63: 812–6.
- 14- Huez I, Bornes S, Bresson D, Créancier L, Prats H. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. *Mol Endocrinol* 2001; 15(12): 2197- 2210.
- 15- Farzadi Haghighi S, Salehi Z, Mohamad RS. Analysis of MnSOD and VEGF genes polymorphisms in Diabetic RetinopathyMolecular and Biochemical diagnosis. *MBD* 2014; 1(1): 13-20.
- 16- Report of the expert committee on the Diagnosis and Classification of diabetes mellitus. *Diabetes Care* 2003; 26: 3160–3167.
- 17- Nakamura S, Iwasaki N, Funatsu H, Kinato S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. *Graefes Arch Clin Exp Ophthalmol* 2009; 247: 21–26.
- 18- Lu Y, Shi Y, Ge Y, Yin J, Huang Z. Two Polymorphisms (Rs699947, Rs2010963) in the VEGFA Gene and Diabetic Retinopathy: An Updated Meta-Analysis. *J Diabetes Metab.* 2012; S 3:006. doi: 10.4172/2155-6156. S3-006
- 19- Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF Gene With Proliferative Diabetic Retinopathy But Not Proteinuria in Diabetes. *Diabetes* 2004; 53: 861–864.

- 322 20- Uthra S, Raman R, Mukesh BN, Rajkumar SA, Padmaja KR, Paul PG,
323 Lakshmipathy P, Gnanamoorthy P, Sharma T, McCarty CA, Kumaramanickavel
324 G. Association of VEGF gene polymorphisms with diabetic retinopathy in a south
325 Indian cohort. *Ophthalmic Genet* 2008; 29(1): 11-15.
- 326 21- Petrovič MG, Korošec P, Košnik M, Osredkar J, Hawlina M, Peterlin B,
327 Petrovič D. Local and genetic determinants of vascular endothelial growth factor
328 expression in advanced proliferative diabetic retinopathy. *Mol vis* 2008; 14 (1):
329 1382–1387.
- 330 22- Bleda S, De-Haro J, Varela C, Esparza L, Ferruelo A, Acin F. Vascular
331 endothelial growth factor polymorphisms are involved in the late vascular
332 complications in Type II diabetic patients. *Diabetes & Vascular Disease Research*
333 2011; 9(1): 68 –74
- 334 23- Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S,
335 Namperumalsamy P, Sundaresan P. Association of VEGF and eNOS gene
336 polymorphisms in type 2 diabetic retinopathy. *Mol Vis* 2006; 12(1): 336-341.
- 337 24- Szaflik JP, Wysocki T, Kowalski M, Majsterek I, Borucka AI, Blasiak J,
338 Szaflik J. An association between vascular endothelial growth factor gene
339 promoter polymorphisms and diabetic retinopathy. *Graefes Arch Clin Exp*
340 *Ophthalmol* 2008; 246: 39–43.

- 341 25- Fouad H, Abdel Hamid MA, Abdel Azeem AA, Labib HM, Khalaf NA.
342 Vascular Endothelial Growth Factor (VEGF) Gene Insertion/Deletion
343 Polymorphism and Diabetic Retinopathy in Patients with Type 2 Diabetes. Journal
344 of American Science: 2011; 7(3): 199- 205.
- 345 26- Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE,
346 Matthews DR. UKPDS 50: Risk Factors for Incidence and Progression of
347 Retinopathy In Type II Diabetes over 6 years from diagnosis. Diabetologia 2001;
348 44; 156-163.
- 349 27- Longo-Mbenza B, Muaka MM, Mbenza G, Mbungu-Fuele S, Mabwa-
350 Mbalanda L, Nzuzi- Babeki V, Mbadi-A-Sungu J. Risk factors of poor control of
351 HBA1c and diabetic retinopathy: Paradox with insulin therapy and high values of
352 HDL in African diabetic patients. Int J Diabetes & Metabolism 2008; 16: 69-78
- 353 28- Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and
354 new questions. Eye 2002; 16:242–260.
- 355 29- UK Prospective Diabetes Study Group. Intensive blood- glucose control with
356 sulphonylureas or insulin compared with conventional treatment risk of
357 complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;
358 352:837–853.
- 359